What is IBS-M?

IBS-M, Irritable Bowel Syndrome-Mixed, is one of the most frustrating and misunderstood forms of IBS. It presents with alternating symptoms of diarrhea and constipation, often in rapid, unpredictable cycles. For patients with IBS-M, this means never knowing how their gut will behave day to day. One morning they’re sluggish and bloated; the next day, they’re sprinting to the bathroom. This unpredictable nature makes IBS-M extremely difficult to manage with conventional treatments, which usually target either diarrhea (IBS-D) or constipation (IBS-C), not both.

The Complexity of Mixed Bowel Patterns

IBS-M is unique in its dual symptom profile. That means patients often get conflicting advice and treatments. Try fiber? It might help constipation but worsens diarrhea. Take an antidiarrheal? Now they’re backed up for days. This seesaw effect can wear down even the most optimistic patient. What IBS-M really needs is a nuanced, individualized approach, one that goes beyond symptom suppression and digs into root causes.

Challenges in Conventional IBS Treatments

Traditional therapies, whether dietary or pharmaceutical, often fall short. Why? Because they’re not personalized. Over-the-counter meds mask symptoms temporarily. Elimination diets are hit or miss, sometimes guided more by trend than science. And the cycle continues: trial, error, frustration, loss of control, reduced social activities, very poor quality of life. This is why IBS-M patients need something smarter, more precise. Something like inFoods IBS.

What Makes inFoods IBS Different for IBS-M Patients?

inFoods IBS is not just another elimination diet or food sensitivity test. It’s a clinically guided, personalized dietary therapy that’s specifically effective for complex IBS cases like IBS-M. What sets inFoods IBS apart is its ability to identify elevated immune responses to specific IBS foods. Each IBS trigger food has been developed with its own individual cut-off that is specific for IBS patients and distinguishes with a high statistical probability between a normal (healthy people) and elevated immune response (IBS patients). The patented technology takes the guess work out. The clear and simple-to-understand results allow patients to easily implement their diet to relief symptoms, consistently and meaningfully.

Conventional food sensitivity tests normally don’t differentiate between a normal physiological or a diseased immunological response. inFoods IBS does, it´s a specific IBS food test. That’s crucial for IBS-M patients, whose mixed symptoms require an especially tailored approach. Instead of managing symptoms with broad-spectrum drugs, inFoods IBS pinpoints the foods provoking an elevated immune response, allowing for a truly customized diet for IBS.

Why Pharmacological Therapy Falls Short for IBS-M

Pharmaceutical options for IBS-M are limited and often ineffective. That's because drugs designed for constipation can worsen diarrhea, and vice versa. It's a balancing act that rarely works in the patient's favor. Moreover, these drugs treat symptoms without addressing the underlying causes, particularly food-triggered immune reactions.

inFoods IBS changes the game by shifting the focus from symptom suppression to root cause identification and offers an implementable solution. It’s not about masking the pain, it’s about identifying IBS food triggers and preventing symptoms like abdominal pain, bloating, and diarrhea.

Clinical Evidence: inFoods IBS Shows Proven Results for IBS-M

What truly elevates inFoods IBS as a game-changing dietary therapy for IBS-M is the clinical data published in the leading journal Gastroenterology. In a pivotal randomized, double-blind, placebo-controlled trial conducted across eight leading U.S. academic medical centers (Mayo Clinic, Cleveland Clinic, Univ. of Michigan, etc.), inFoods IBS was evaluated for its effectiveness in reducing IBS symptoms like pain and bloating.

Here’s what the study found, specific to IBS-M patients:

• 66.0% of IBS-M patients in the inFoods IBS treatment group achieved the FDA’s primary endpoint for abdominal pain reduction.
• In contrast, only 29.5% of IBS-M patients in the placebo group had a relief in abdominal pain.
• This difference - 36.5% - represents a statistically significant improvement, clearly demonstrating the effectiveness of the inFoods IBS guided dietary therapy.
• Across all IBS patients (including all subtypes), 59.6% of patients in the inFoods IBS treatment group experienced a clinically meaningful reduction in abdominal pain, compared to 42.2% in the control group.

These results confirm that inFoods IBS is not only effective, it’s especially powerful and the first therapeutic and targeted approach for IBS-M patients. It outperforms standard treatments and is not comparable at all with generic food sensitivity tests.

‍

Ready to find out which foods might be causing your IBS-M symptoms?

‍inFoods IBS can also be your solution to identify your trigger foods: Find relief, reduce your frustration, regain control of your life and return to your social activities. inFoods IBS as a new breakthrough dietary therapy that helps you to improve your quality of life and be yourself again.

‍Discover your personal IBS trigger foods with inFoods IBS